CytoDyn (CYDY) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing leronlimab for solid-tumor oncology indications, including colorectal and triple-negative breast cancer.

• Current strategy includes advancing Phase II trials in relapsed/refractory micro-satellite stable colorectal cancer and exploring additional oncology indications.

• Research and development efforts are ongoing for a new or modified long-acting version of leronlimab.

Financial performance and metrics

• Identified as a "smaller reporting company" under SEC rules, allowing for reduced disclosure obligations and only two years of audited financials.

• Accumulated deficit of approximately $887.8 million as of May 31, 2025, restricting the ability to pay dividends under Delaware law.

• Auditors have expressed substantial doubt about the company's ability to continue as a going concern for fiscal years ended May 31, 2024 and 2025.

Use of proceeds and capital allocation

• Net proceeds from securities sales and any exercise of convertible securities will be used for working capital and general corporate purposes.

• Pending use, proceeds may be invested in short-term, interest-bearing or investment-grade securities.